Clinical trials: PSA
Parkinsons Disease (PD)
Directional PSA Versus STN DBS for TD-PD
The aim of this study is to compare the effectiveness of the deep brain stimulation in the posterior subthalamic area (PSA) versus the subthalamic nucleus (STN) using directional lead for the treatment of tremor-dominant…
- Trial name
- NCT07700862
- Testing
- directional Deep brain stimulation
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Ruijin Hospital
Prostate Cancer
Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer
Some patients with prostate cancer benefit from androgen deprivation therapy which reduces levels of testosterone. Leuprolide is a synthetic Luteinizing hormone releasing hormone (LHRH) analogue which upon administration can…
- Trial name
- NCT01415960
- Testing
- Leuprolide acetate 22.5 mg depot, GP-Pharm SA
- Where
- 25 sites in United States
- Volunteers
- 163 people
- Sponsor
- GP-Pharm
Prostate Cancer
Chemotherapy, Hormone Therapy, and Surgery to Remove the Prostate Gland in Patients With High Risk Prostate Cancer
In men with prostate cancer who do not have evidence of spread to bone or other sites on computed axial tomography (CAT) scan/bone scan but are still at significant risk of failing treatment with surgery or radiation alone, a…
- Trial name
- NCT00108290
- Testing
- Chemotherapy
- Where
- United States
- Sponsor
- US Department of Veterans Affairs
Prostate Cancer
ExosomeDx in MRI-negative Men With High PSA
Magnetic resonance imaging (MRI) has become the current standard of care in risk stratifying men with an elevated Prostate-specific antigen (PSA) to determine who needs to undergo prostate biopsy, which is invasive and carries a…
- Trial name
- NCT06966089
- Testing
- Urinary ExoDx test, Transrectal ultrasound-guided prostate biopsy, Transperineal 12-core prostate biopsy
- Where
- 6 sites in United States
- Volunteers
- 425 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Prostatic Neoplasms, Prostate-Specific Antigen
Prognostic Study of Prostate Cancer Via Dynamic Change of PSA in Peritoneal Drainage Fluid After Radical Prostatectomy
This study investigates the prognostic value of dynamic changes in Prostate-Specific Antigen (PSA) levels found in the peritoneal drainage fluid after radical prostatectomy.
- Trial name
- NCT06608225
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Prostate Cancer
Screening for Prostate Cancer Among Those Prostate-specific Antigen Value Between 2.5 and 4.0 ng/mL
The study aims to evaluate the detection rate and characteristics of prostate cancer among males with PSA values between 2.5 and 4.0 ng/mL in Nanjing, meanwhile, to access the effectiveness of conducting multi-parametric MRI…
- Trial name
- NCT04317625
- Testing
- mpMRI scanning
- Where
- China
- Volunteers
- 232 people, healthy volunteers welcome
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Prostate Cancer
Biomarker Study of in Men With PSA Progression on Abi for CR or CS PC (Bio-STAMP)
This is a multicenter, Phase II randomized biomarker-based therapeutic study in metastatic prostate cancer experiencing prostate specific antigen (PSA) only progression (without visceral, bone or lymph node progression) while on…
- Trial name
- NCT05705700
- Testing
- Dutasteride, Abiraterone
- Sponsor
- Masonic Cancer Center, University of Minnesota
Prostatic Neoplasm
Determination of the Diagnostic Detection Rate of Axumin (Fluciclovine) Digital PET/CT, Post-prostatectomy
Fluciclovine F18 (Axumin) has been demonstrated to provide good delineation of recurrence of prostate cancer after definitive therapies.
- Trial name
- NCT04234399
- Testing
- Fluciclovine PET/CT using a digital PET/CT
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Vermont
Prostate Cancer
Focal Brachytherapy in Patients With Selected "Low-risk" Prostate Cancer - a Phase-II-trial
This trial examines the feasibility and toxicity of focal brachytherapy in patients with low-risk prostate cancer.
- Trial name
- FOKAL-BT (NCT02391051)
- Testing
- HDR-Brachytherapy
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- University of Erlangen-Nürnberg Medical School
Prostate Cancer
Evaluation of an MRI-based Prostate Cancer Screening Program (VISIONING): 5-Year Follow-up Round (VISIONING III)
Prostate cancer remains one of the leading causes of cancer-related morbidity and mortality among men. While PSA-based screening has been associated with reduced prostate cancer mortality, it also results in substantial…
- Trial name
- Visioning III (NCT07762911)
- Testing
- MRI
- Where
- Switzerland
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Patients Scheduled for Prostate Biopsy Because of Increased Serum PSA and/or Abnormal Digital Rectal Examination
Medical Economics of Urinary PCA3 Test for Prostate Cancer Diagnosis
The ultrasound-guided biopsies of the prostate is the validated technique for the diagnosis of prostate cancer, the first human cancer and second leading cause of cancer death.
- Trial name
- NCT01632930
- Testing
- urinary PCA3 test using Progensa® PCA3 assay kit (Gen-Probe)
- Where
- 10 sites in France
- Volunteers
- 962 people
- Sponsor
- Hospices Civils de Lyon
Prostate Cancer
3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy
In April 2011, the United States Food and Drug Administration (FDA) approved the oral drug abiraterone acetate (Zytiga ®) in combination with prednisone (a steroid) to treat patients with metastatic castration-resistant prostate…
- Trial name
- NCT01751451
- Testing
- Abiraterone acetate, Abiraterone acetate plus degarelix, Degarelix
- Where
- 16 sites in United States
- Volunteers
- 124 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Prostate Cancer
Targeted Prostate Biopsy Using a Novel MRI-Ultrasound Fusion Device
The purpose of this study is to evaluate the effectiveness of Focal-Fusion Bx at detecting clinically significant prostate cancer in a standard clinical environment.
- Trial name
- NCT02524860
- Testing
- Focal-Fusion Bx
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Focal Healthcare Inc.
Prostatic Neoplasms
The Application Value of 18F-prostate-specific Membrane Antigen PET/CT in Prostate Cancer
Prostate cancer (PCa) is the most common type of malignant tumor and the third leading cause of cancer-associated mortality among men worldwide.
- Trial name
- NCT04521894
- Testing
- Positron emission tomography/computerized tomography (PET/CT)
- Where
- China
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Prostate Cancer, BRCA Mutation
The IMPACT Study - Identification of Men With a Genetic Predisposition to ProstAte Cancer
The IMPACT study is an international targeted prostate screening study of men at increased prostate cancer risk due to the presence of known pathogenic mutations in BRCA1 and BRCA2 genes and Mis-Match Repair genes (MLH1, MSH6…
- Conditions
- Prostate Cancer, BRCA Mutation, Mismatch Repair Gene Mutation, Genetic Predisposition to Disease
- Trial name
- NCT00261456
- Testing
- PSA test, Prostate Biopsy
- Where
- United Kingdom
- Volunteers
- 3,500 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Prostate Cancer
Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of vaccine therapy in treating patients who have metastatic prostate cancer.
- Trial name
- NCT00004211
- Testing
- PSA RNA-pulsed dendritic cell vaccine
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Duke University
Prostate Cancer
Does Protein Restriction Inhibit Prostrate Cancer Growth
The Purpose of the Protein Study is to investigate whether a reduced protein diet can inhibit the growth of prostate cancer in humans.
- Trial name
- NCT01692587
- Testing
- Protein restrictive diet
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Washington University School of Medicine
Chronic Pseudomonas Aeruginosa Infection, Cystic Fibrosis (CF)
Study With Phage for CF Subjects With Pseudomonas Lung Infection
The goal of this Phase 2b clinical trial is to see if nebulized phage (BX004) can treat chronic Pseudomonas aeruginosa (PsA) lung infection in CF subjects.
- Trial name
- NCT06998043
- Testing
- BX004
- Where
- 14 sites in United States
- Volunteers
- 63 people
- Sponsor
- BiomX Ltd
Prostate Cancer
Study of ATN-224 in Patients With Prostate Cancer
This is a multicenter, randomized, phase II study of the safety and efficacy of two dose levels of oral ATN-224 in patients with prostate cancer with a rising serum PSA in the absence of detectable disease.
- Trial name
- NCT00405574
- Testing
- ATN-224
- Where
- 6 sites in United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Attenuon
Prostate Cancer (Diagnosis), Prostate-Specific Antigen
Intraprostatic Anesthesia During Transperineal Prostate Biopsy
Transperineal prostate biopsy has become the standard method for diagnosing prostate cancer because of its favorable safety profile and low infectious complication rates.
- Trial name
- PRO-PAIN (NCT07683182)
- Testing
- Prilocaine, Bupivacaine, Perineal Local Anesthesia
- Where
- Turkey (Türkiye)
- Volunteers
- 50 people
- Sponsor
- Marmara University